Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGN4BY)

Drug Name
Flurbiprofen Drug Info
Synonyms
Adfeed; Adofeed; Anmetarin; Ansaid; Anside; Antadys; Cebutid; FLP; Flubiprofen; Flugalin; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Fluriproben; Flurofen; Froben; Ocufen; Ocuflur; Stayban; Yakuban; Zepolas; FLURBIPROFEN SODIUM; Froben Sr; BTS 18322; F0371; FP 70; IN1332; U 27182; Ansaid (TN); Apo-Flurbiprofen; BTS-18322; Flurbiprofene [INN-French]; Flurbiprofeno [INN-Spanish]; Flurbiprofenum [INN-Latin]; Froben (TN); MKS-11; Novo-Flurprofen; Nu-Flurbiprofen; U 27,182; U-27182; L-790,330; Flurbiprofen (JP15/USP/INN); Flurbiprofen [USAN:INN:BAN:JAN]; [+/-]-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (+/-)-2-Fluoro-alpha-methyl[1,1′ -biphenyl]-4-acetic Acid; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; 3-Fluoro-4-phenylhydratropic acid
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Therapeutic Class
Antiinflammatory Agents
Cross-matching ID
PubChem CID
3394
ChEBI ID
CHEMBL563
CAS Number
CAS 5104-49-4
TTD Drug ID
DMGN4BY
VARIDT Drug ID
DR00587
INTEDE Drug ID
DR0731
ACDINA Drug ID
D00287

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [14]
Naproxen DMZ5RGV Bursitis Approved [15]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [16]
Indomethacin DMSC4A7 Bursitis Approved [17]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [18]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [19]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [20]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [21]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [17]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [23]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [24]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [25]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [26]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [29]
Metronidazole DMTIVEN Abscess Approved [30]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [31]
Ethanol DMDRQZU Chronic pain MG30 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [33]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [34]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [35]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [36]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [37]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [36]
Verapamil DMA7PEW Angina pectoris BA40 Approved [38]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [39]
Estrone DM5T6US Acne vulgaris ED80 Approved [40]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 2B7 (UGT2B7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [42]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [43]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [6]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [44]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [45]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [6]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [46]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [48]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [49]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A3 (UGT1A3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [50]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [6]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [51]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [52]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [46]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [53]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [49]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [54]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [50]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [55]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [6]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [56]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [6]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [6]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [57]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [6]
Haloperidol DM96SE0 Delirium Approved [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Amyloid-beta precursor protein (APP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [58]
Selenium DM25CGV N. A. N. A. Approved [59]
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [61]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [62]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [63]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [65]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [66]
Aluminium DM6ECN9 Hyperhidrosis EE00 Approved [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [68]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [9]
Diazepam DM08E9O Alcohol withdrawal Approved [69]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [70]
Desogestrel DM27U4Y Contraception QA21 Approved [70]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [9]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [9]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [71]
Quercetin DM3NC4M Obesity 5B81 Approved [72]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [9]
Diazepam DM08E9O Alcohol withdrawal Approved [69]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [74]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [75]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [9]
Quercetin DM3NC4M Obesity 5B81 Approved [76]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [77]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [9]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [78]
Testosterone DM7HUNW Hot flushes GA30 Approved [79]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [80]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [9]
Diazepam DM08E9O Alcohol withdrawal Approved [69]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [81]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [9]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [9]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [82]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [83]
Ethacrynic acid DM60QMR Edema MG29 Approved [81]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Metalloproteinase inhibitor 1 (TIMP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pentoxifylline DMU3DNC Alcoholic hepatitis DB94.1 Approved [84]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [85]
Verapamil DMA7PEW Angina pectoris BA40 Approved [86]
Selenium DM25CGV N. A. N. A. Approved [87]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [86]
Quercetin DM3NC4M Obesity 5B81 Approved [88]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [89]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [90]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [91]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [92]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Albumin (ALB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [93]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [84]
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [94]
Diazepam DM08E9O Alcohol withdrawal Approved [95]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [96]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [97]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [98]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [99]
Methotrexate DM2TEOL Anterior urethra cancer Approved [100]
Quercetin DM3NC4M Obesity 5B81 Approved [101]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Eukaryotic translation initiation factor 4E (EIF4E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [102]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [103]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [104]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [105]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [106]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [12]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [107]
Momelotinib DMF98Q0 Myelofibrosis 2A20.2 Approved [108]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [109]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [110]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Tumor necrosis factor receptor superfamily member 16 (NGFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [111]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [112]
Methotrexate DM2TEOL Anterior urethra cancer Approved [113]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [114]
Panobinostat DM58WKG Chronic graft versus host disease Approved [115]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [13]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [13]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [116]
Oxaprozin DM9UB0P Osteoarthritis FA00-FA05 Approved [117]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [118]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 15-hydroxyprostaglandin dehydrogenase (HPGD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [119]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [120]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [121]
Testosterone DM7HUNW Hot flushes GA30 Approved [122]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [7]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [122]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [118]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [123]
Mifepristone DMGZQEF Cushing disease 5A70 Approved [124]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [125]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [11]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [11]
Methotrexate DM2TEOL Anterior urethra cancer Approved [60]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [89]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [126]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [126]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [11]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [11]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Modulator [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) Main DME DE5IED8 CP2C9_HUMAN Substrate [4]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [5]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [6]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [6]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Gene/Protein Processing [7]
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [8]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [9]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [9]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [9]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Protein Interaction/Cellular Processes [10]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Gene/Protein Processing [11]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Post-Translational Modifications [12]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Gene/Protein Processing [7]
Tumor necrosis factor receptor superfamily member 16 (NGFR) OTPKSM49 TNR16_HUMAN Gene/Protein Processing [13]

References

1 Flurbiprofen FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4194).
3 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
4 Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
5 Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7.
6 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
7 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
8 Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study. J Pharmacokinet Biopharm. 1997 Feb;25(1):63-77. doi: 10.1023/a:1025719827072.
9 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
10 In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents. Pharmacol Res. 2007 Apr;55(4):318-28.
11 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
12 The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells. Cancer Res. 2007 Dec 1;67(23):11402-10. doi: 10.1158/0008-5472.CAN-07-1792.
13 A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14. doi: 10.1007/s00280-007-0462-3. Epub 2007 Apr 20.
14 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
15 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
16 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
18 Pfizer. Product Development Pipeline. March 31 2009.
19 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
20 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
21 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
22 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
23 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
24 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
25 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
26 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
27 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
28 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
29 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
30 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
31 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
32 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
33 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
34 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
35 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
36 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
37 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
38 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
39 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
40 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
41 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
42 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
43 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
44 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
45 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
46 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
47 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
48 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
49 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
50 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
51 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
52 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
53 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
54 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
55 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
56 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
57 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
58 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
59 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
60 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
61 Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
62 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
63 Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
64 Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
65 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
66 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
67 Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
68 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
69 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
70 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
71 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
72 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
73 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
74 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
75 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
76 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
77 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
78 Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
79 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
80 Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
81 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
82 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
83 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
84 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
85 Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 2012 Apr;26(4):1535-48. doi: 10.1096/fj.11-198184. Epub 2011 Dec 23.
86 Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
87 Inhibition of invasion and induction of apoptosis by selenium in human malignant brain tumour cells in vitro. Int J Oncol. 2007 May;30(5):1263-71.
88 Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res. 2001 Sep 1;480-481:269-76. doi: 10.1016/s0027-5107(01)00184-1.
89 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
90 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
91 Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem. 2005 Aug 1;95(5):955-69. doi: 10.1002/jcb.20452.
92 Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83(1):18-25. doi: 10.1159/000166183. Epub 2008 Oct 30.
93 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
94 A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
95 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
96 Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
97 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
98 Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
99 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
100 Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
101 Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
102 Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2022 Jan 15;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.
103 Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
104 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
105 Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.
106 A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
107 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
108 The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
109 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
110 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
111 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
112 Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
113 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
114 TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18952-7. doi: 10.1073/pnas.1221172110. Epub 2013 Nov 4.
115 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
116 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
117 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
118 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
119 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
120 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
121 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
122 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
123 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
124 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
125 Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
126 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.